December 19, 2017 / 12:42 PM / a year ago

BRIEF-Onconova Therapeutics Announces License And Collaborative Development Agreement With Hanx Biopharma

Dec 19 (Reuters) - Onconova Therapeutics Inc:

* ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AND COLLABORATIVE DEVELOPMENT AGREEMENT WITH HANX BIOPHARMACEUTICALS FOR ON 123300, A DUAL INHIBITOR OF CDK4/6 + ARK5

* ONCONOVA THERAPEUTICS INC - HANX WILL FUND STUDIES TOWARDS INVESTIGATIONAL NEW DRUG APPLICATIONS IN BOTH U.S. AND CHINA

* ONCONOVA THERAPEUTICS INC - AGREEMENT INCLUDES LICENSING FEE, CUSTOMARY MILESTONE PAYMENTS AND ROYALTIES ON SALES OF ON 123300

* ONCONOVA THERAPEUTICS INC - HANX TO COMMERCIALIZE ON 123300 IN GREATER CHINA, ONCONOVA RETAINS RIGHTS IN REST OF WORLD Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below